CURAGEN AI LABS

From the company

CuraGenAI designs disease-modifying small molecules for hard-to-treat diseases and accelerates target-to-lead discovery by combining generative AI, reinforcement learning, and ML model architectures with biology and structure-based validation. Its CureRX platform delivers synthesis-ready lead series to pharma and biotech partners, compressing target-to-lead discovery from years to weeks. Selected programs advance toward clinical translation through CuraGen Neuro Therapeutics, including a brain-directed ACAT1/SOAT1 program in glioblastoma.